Gilead Sciences has appointed Kevin Young as its new chief operating officer, while Martin Silverstein takes on the role of executive vice president, strategy.
Young (pictured right) first joined the biopharmaceutical firm in 2004, serving as its executive vice president of commercial operations, and has been a senior advisor to the company since 2014.
He has over 20 years of experience in the biopharmaceutical industry, having held the position of director of operations at ICI Pharmaceuticals and then head of business operations at Amgen.
Dr John Milligan, president and chief executive of Gilead, said: “I am delighted to welcome Kevin back to Gilead in a full-time capacity.
“Kevin’s knowledge of Gilead’s business, all aspects of commercial operations and our therapeutic areas of focus, his commitment to operational excellence, and his leadership capabilities make him an obvious choice for the role.”
Meanwhile, in his new role Silverstein (pictured left) will take responsibility for the firm’s corporate development, commercial planning and alliance management functions.
He brings over 30 years of healthcare strategy expertise to Gilead, having most recently served as executive vice president and chief strategy officer at Anthem.
Prior to this, Silverstein spent 28 years at The Boston Consulting Group, and held a number of senior positions including global leader of its healthcare practice, senior partner and managing director.
Milligan said: “I’m very pleased to welcome Marty to the Gilead team.
“His vast expertise in the healthcare sector, across biopharmaceuticals, pharmacy benefit management, health insurance and healthcare delivery, will be of great value to Gilead as we see the complexity of our business increase around the world.”